Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis
Open Access
- 5 November 2012
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 209 (12), 2149-2156
- https://doi.org/10.1084/jem.20121274
Abstract
The apolipoprotein E (APOE) ε4 allele is the strongest genetic risk factor for Alzheimer’s disease (AD). The influence of apoE on amyloid β (Aβ) accumulation may be the major mechanism by which apoE affects AD. ApoE interacts with Aβ and facilitates Aβ fibrillogenesis in vitro. In addition, apoE is one of the protein components in plaques. We hypothesized that certain anti-apoE antibodies, similar to certain anti-Aβ antibodies, may have antiamyloidogenic effects by binding to apoE in the plaques and activating microglia-mediated amyloid clearance. To test this hypothesis, we developed several monoclonal anti-apoE antibodies. Among them, we administered HJ6.3 antibody intraperitoneally to 4-mo-old male APPswe/PS1ΔE9 mice weekly for 14 wk. HJ6.3 dramatically decreased amyloid deposition by 60–80% and significantly reduced insoluble Aβ40 and Aβ42 levels. Short-term treatment with HJ6.3 resulted in strong changes in microglial responses around Aβ plaques. Collectively, these results suggest that anti-apoE immunization may represent a novel AD therapeutic strategy and that other proteins involved in Aβ binding and aggregation might also be a target for immunotherapy. Our data also have important broader implications for other amyloidosis. Immunotherapy to proteins tightly associated with misfolded proteins might open up a new treatment option for many protein misfolding diseases.Keywords
This publication has 26 references indexed in Scilit:
- Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide ClearanceScience Translational Medicine, 2011
- Alzheimer’s Disease: The Challenge of the Second CenturyScience Translational Medicine, 2011
- Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm ShiftNeuron, 2011
- Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ ClearanceNeuron, 2009
- Immune Activation in Brain Aging and Neurodegeneration: Too Much or Too Little?Neuron, 2009
- The Role of Apolipoprotein E in Alzheimer's DiseaseNeuron, 2009
- apoE isoform–specific disruption of amyloid β peptide clearance from mouse brainJCI Insight, 2008
- Active and Passive Immunotherapy for Neurodegenerative DisordersAnnual Review of Neuroscience, 2008
- ApoE Promotes the Proteolytic Degradation of AβNeuron, 2008
- Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's diseaseProceedings of the National Academy of Sciences of the United States of America, 2006